Drugs / lotiglipron
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 110 trials | ||||||
| Phase 1 | NCT05788328 | Mar → Sep 2023 | — | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT05745701 | Feb → May 2023 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05671653 | Jan → Nov 2023 | obesity disorder | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT05677867 | Jan → Mar 2023 | obesity disorder | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05652647 | Dec 2022 → Mar 2023 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05510245 | Aug 2022 → Jul 2023 | impaired renal function disease, type 2 diabetes mellitus | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT05478603 | Aug 2022 → Apr 2023 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05158244 | Dec 2021 → Jun 2022 | type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04305587 | Mar 2020 → Jul 2021 | type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04148209 | Nov 2019 → Mar 2020 | — | Pfizer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05579977 | Oct 2022 → Jul 2023 | obesity disorder, type 2 diabetes mellitus | Pfizer | Terminated | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-12-21 | Nxera Pharma UK Limited | Sosei Heptares' Partner Pfizer Progresses its Oral GLP-1 Receptor Agonist PF-07081532 into Ph2 Clinical Trials for Treating Type2 Diabetes and Obesity nxera.life ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lotiglipron | “AIM: To investigate the effects of lotiglipron (PF-07081532), a once-daily, oral small-molecule glucagon-like peptide-1 receptor agonist, in participants with type 2 diabetes...” PMID 38751362 ↗ May 20242“The aim was to investigate the effects of lotiglipron, a once-daily, oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist, in participants with type 2 diabetes...” PMID 39415344 ↗ Oct 2024 “Assessment of the Drug-Drug Interaction Potential of Lotiglipron (PF-07081532)” PMID 42053447 ↗ May 2026 |
| Known as | PF-07081532 | “AIM: To investigate the effects of lotiglipron (PF-07081532), a once-daily, oral small-molecule glucagon-like peptide-1 receptor agonist, in participants with type 2 diabetes...” PMID 38751362 ↗ May 20249“Assessment of the Drug-Drug Interaction Potential of Lotiglipron (PF-07081532)” PMID 42053447 ↗ May 2026 |
| Action | Activate | “glucagon-like peptide-1 receptor agonist” PMID 38751362 ↗ May 2024 |
| Modality | Small molecule | “once-daily, oral small-molecule glucagon-like peptide-1 receptor agonist” PMID 38751362 ↗ May 2024 |
| Route | Oral | “single ascending oral doses of PF-07081532” NCT04148209 ↗ |